Molbio Diagnostics IPO Listing: GMP Indicates Nearly 20% Premium Ahead of August 17 Debut

Molbio Diagnostics IPO Listing in Focus as GMP Indicates Nearly 20% Premium

Molbio Diagnostics is set to make its debut on the Indian stock exchanges on Monday, August 17, 2026, following strong demand during its initial public offering.

The IPO received an overall subscription of around 70 times, highlighting significant investor participation during the issue period.

The share allotment process was finalised on Thursday, August 13, and investors who participated in the IPO can check their allotment status through the registrar and stock exchange platforms.

Molbio Diagnostics IPO Highlights

IPO Issue Price: ₹807 per share

IPO Price Band: ₹768–₹807

Latest Reported GMP: ₹156

Indicative Listing Price: ₹963

Indicative Premium: 19.3%

Overall Subscription: 70 times

Listing Date: August 17, 2026

Stock Exchanges: NSE and BSE

IPO Registrar: KFin Technologies

Molbio Diagnostics IPO GMP

The latest reported grey market premium for Molbio Diagnostics shares stood at around ₹156 on Friday morning.

Based on the upper end of the IPO price band at ₹807 and the reported GMP, the indicative price works out to approximately ₹963 per share.

This represents an indicative premium of around 19.3% over the IPO issue price.

However, grey market premiums are unofficial market indicators and may change before the actual listing. The final listing price is determined by market conditions and trading activity on the stock exchanges.

Strong Subscription Response

The Molbio Diagnostics IPO opened for public subscription on August 10, 2026, and closed on August 12, 2026.

The issue received an overall subscription of approximately 70 times.

The retail investor portion was subscribed around 13 times, while the non-institutional investor category received approximately 50 times subscription.

The strong subscription response has kept attention focused on the company's upcoming stock market debut.

Molbio Diagnostics IPO Details

The IPO had a price band of ₹768 to ₹807 per share.

The fresh issue was aimed at raising approximately ₹200 crore.

The IPO also included an offer for sale of 91.66 lakh shares, aggregating to approximately ₹739.70 crore.

The company plans to utilise proceeds from the fresh issue for various business and expansion-related requirements.

How Molbio Diagnostics Plans to Use IPO Funds

According to the information provided in the source, Molbio Diagnostics intends to use the net proceeds from the fresh issue for establishing a research and development facility and centre of excellence.

The facility will be operated by the company's wholly-owned subsidiary, Bigtec.

The company also plans to use funds for capital expenditure related to connected office space for the company, its subsidiaries and associates.

A portion of the proceeds is also planned for purchasing plant, machinery and other equipment for its Goa Unit I, Goa Unit II and Visakhapatnam Unit.

The remaining funds are intended for general corporate purposes.

About Molbio Diagnostics

Molbio Diagnostics is a point-of-care diagnostics company focused on developing and expanding access to rapid and cost-effective diagnostic technologies.

The company's products are aimed at supporting the diagnosis of infectious and non-communicable diseases.

The company operates across the diagnostics segment and has been expanding its business and product portfolio.

Revenue and Profit Growth

Molbio Diagnostics has reported steady growth in revenue over the last three financial years.

Revenue from operations stood at

Net profit attributable to the owners of the parent stood at

The financial numbers indicate continued growth in both revenue and profitability during the period covered in the source.

IPO Listing Date and Allotment

The Molbio Diagnostics IPO is scheduled to list on both the NSE and BSE on Monday, August 17, 2026.

The IPO allotment was finalised on Thursday.

Investors can check their allotment status through the IPO registrar, KFin Technologies, as well as through the relevant stock exchange platforms.

What to Watch Before the Listing

The upcoming listing will be closely watched following the IPO's strong subscription response and the reported grey market premium.

Key factors to watch include

The reported GMP should be viewed only as an unofficial market indication and should not be treated as a guarantee of the actual listing price.

Key Takeaways

Disclaimer

This article is published solely for educational and informational purposes and should not be considered financial, investment, legal, or tax advice.

TrendRipperX is not registered with the Securities and Exchange Board of India (SEBI) as an Investment Adviser or Research Analyst. The information presented in this article is based on publicly available information and is intended only for general awareness.

This article does not constitute a recommendation to buy, sell, or hold any security. Grey market premiums are unofficial and can change rapidly. The actual listing price may differ significantly from GMP-based estimates.

Readers should conduct their own research and consult a SEBI-registered financial professional before making any investment decisions.